(Q33394505)

English

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Do-Youn Oh

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Keun Wook Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kyung-Hee Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chang-Hak Sohn

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Young Suk Park

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dae Young Zang

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hun-Mo Ryoo

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hong-Suk Song

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jin-Soo Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hye-Jin Kang

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bong-Seog Kim

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

15 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1164-1174

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-011-9651-3

0 references

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

The calculation of actual or received dose intensity: a comparison of published methods.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Cancer pharmacogenetics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

The pharmacogenetics research network: from SNP discovery to clinical drug response.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Genetics of the variable expression of CYP3A in humans

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9651-3

21 January 2018

Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line

1 reference

https://pubmed.ncbi.nlm.nih.gov/21404106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://pubmed.ncbi.nlm.nih.gov/21404106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21404106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21404106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/21404106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical characteristics of gemcitabine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21404106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9651-3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33394505&oldid=1987421554"